Compare LION & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LION | RLAY |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.8B |
| IPO Year | 2025 | 2020 |
| Metric | LION | RLAY |
|---|---|---|
| Price | $12.33 | $17.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 13 |
| Target Price | $15.08 | ★ $27.58 |
| AVG Volume (30 Days) | ★ 3.4M | 2.3M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.78 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,631,800,000.00 | $15,355,000.00 |
| Revenue This Year | $27.40 | N/A |
| Revenue Next Year | $2.10 | $60.15 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 53.44 |
| 52 Week Low | $6.43 | $5.95 |
| 52 Week High | $16.70 | $21.27 |
| Indicator | LION | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 56.57 | 47.15 |
| Support Level | $11.88 | $16.68 |
| Resistance Level | $12.58 | $20.09 |
| Average True Range (ATR) | 0.57 | 0.96 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 66.54 | 42.01 |
Lionsgate Studios Corp is a motion picture and television studio operations aligned with the STARZ premium subscription platform to bring a varied portfolio of entertainment to consumers around the world. The group has two reportable business segments: the Motion Picture and Television Production reportable segments. Motion Picture consists of the development and production of feature films, the acquisition of North American and world-wide distribution rights. Television Production consists of the development, production, and world-wide distribution of television productions, including television series, television movies and mini-series, and non-fiction programming.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.